We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA Extraction Technique Improved for Chagas Diagnosis

By LabMedica International staff writers
Posted on 28 Jan 2019
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is endemic in many parts of the Americas, where six to seven million people are infected. More...
In the acute phase of the infection, serology may still be negative but positive for parasite by microscopic examination or by culture in specialized medium.

The Polymerase Chain Reaction (PCR) has become an important and sensitive diagnostic tool. The test is highly sensitive for diagnosis of acute and congenital Chagas disease. Conventional PCR has several drawbacks, especially cross-contamination. For this reason, quantitative PCR (qPCR) has now been more widely used and accepted.

Scientists at the Cayetano Heredia University (Lima, Peru) and their colleagues improved and developed a more sensitive method to recover parasite DNA from clot samples for the diagnosis of Chagas disease. A total of 265 match pair samples of whole blood–guanidine (GEB) and clot samples were analyzed; 150 were from Chagas seropositive subjects. DNA was extracted from both whole blood-guanidine samples, using a previously standardized methodology, and from clot samples, using a newly developed methodology based on a combination of the FastPrep technique and the standard method for GEB extraction.

The blood samples mixed with Guanidine/EDTA (GEB) were processed using the High Pure PCR Template Preparation kit. A duplex qPCR was performed targeting the satellite sequence of the nuclear genome of T. cruzi and the sequence of an internal amplification control. The diagnosis of Chagas disease in human samples was based on serological assays. Enzyme-linked immunosorbent assays (ELISA) were performed using Chagatek Wiener Recombinante v3.0 ELISA. Indirect hemagglutination assay (IHA) was performed using the Chagas Polychaco kit. Western blot analyses were also performed.

The team reported that out of the 265 samples analyzed, 150 samples were from Chagas seropositive individuals. The mean DNA concentration was higher on clot samples than in GEB samples. Of the 150 samples from Chagas positive individuals by serology, 47 samples tested positive by qPCR with DNA extracted by both GEB and clot, but an additional 13 samples tested positive only in DNA extracted from clot. No serology-negative samples resulted positive when tested by qPCR. The agreement between the qPCR using clot DNA and GEB DNA was 95.9%.

The authors concluded that their improved methodology for the detection of T. cruzi DNA using clot samples which might improve early diagnosis and therefore will improve treatment and prognosis of infected individuals, especially of those with low blood loads of parasites. The study was published on January 11, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Cayetano Heredia University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.